Use of the Win Ratio Analysis in Critical Care Trials
Composite outcomes are commonly used in critical care trials to estimate the treatment effect of an intervention. A significant limitation of classical analytic approaches is that they assign equal statistical importance to each component in a composite, even if these do not have the same clinical importance (i.e., in a composite of death and organ failure, death is clearly more important). The win ratio (WR) method has been proposed as an alternative for trial outcomes evaluation, as it effectively assesses events based on their clinical relevance (i.e., hierarchical order) by comparing each patient in the intervention group with their counterparts in the control group. This statistical approach is increasingly used in cardiovascular outcome trials. However, WR may be useful to unveil treatment effects also in the critical care setting, because these trials are typically moderately sized, thus limiting the statistical power to detect small differences between groups, and often rely on composite outcomes that include several components of different clinical importance. Notably, the advantages of this approach may be offset by several drawbacks (such as ignoring ties and difficulties in selecting and ranking endpoints) and challenges in appropriate clinical interpretation (i.e., establishing clinical meaningfulness of the observed effect size). In this perspective article, we present some key elements to implementing WR statistics in critical care trials, providing an overview of strengths, drawbacks, and potential applications of this method. To illustrate, we conduct a reevaluation of the HYPO-ECMO (Hypothermia during Venoarterial Extracorporeal Membrane Oxygenation) trial using the WR framework as a case example.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:209 |
|---|---|
| Enthalten in: |
American journal of respiratory and critical care medicine - 209(2024), 7 vom: 01. Apr., Seite 798-804 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Monzo, Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiogenic shock |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 03.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1164/rccm.202309-1644CP |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36776010X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36776010X | ||
| 003 | DE-627 | ||
| 005 | 20240403235325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1164/rccm.202309-1644CP |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM36776010X | ||
| 035 | |a (NLM)38285595 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Monzo, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of the Win Ratio Analysis in Critical Care Trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Composite outcomes are commonly used in critical care trials to estimate the treatment effect of an intervention. A significant limitation of classical analytic approaches is that they assign equal statistical importance to each component in a composite, even if these do not have the same clinical importance (i.e., in a composite of death and organ failure, death is clearly more important). The win ratio (WR) method has been proposed as an alternative for trial outcomes evaluation, as it effectively assesses events based on their clinical relevance (i.e., hierarchical order) by comparing each patient in the intervention group with their counterparts in the control group. This statistical approach is increasingly used in cardiovascular outcome trials. However, WR may be useful to unveil treatment effects also in the critical care setting, because these trials are typically moderately sized, thus limiting the statistical power to detect small differences between groups, and often rely on composite outcomes that include several components of different clinical importance. Notably, the advantages of this approach may be offset by several drawbacks (such as ignoring ties and difficulties in selecting and ranking endpoints) and challenges in appropriate clinical interpretation (i.e., establishing clinical meaningfulness of the observed effect size). In this perspective article, we present some key elements to implementing WR statistics in critical care trials, providing an overview of strengths, drawbacks, and potential applications of this method. To illustrate, we conduct a reevaluation of the HYPO-ECMO (Hypothermia during Venoarterial Extracorporeal Membrane Oxygenation) trial using the WR framework as a case example | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cardiogenic shock | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a critical care | |
| 650 | 4 | |a heart failure | |
| 700 | 1 | |a Levy, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Baudry, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Combes, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Ouattara, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Delmas, Clément |e verfasserin |4 aut | |
| 700 | 1 | |a Kimmoun, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Girerd, Nicolas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of respiratory and critical care medicine |d 1994 |g 209(2024), 7 vom: 01. Apr., Seite 798-804 |w (DE-627)NLM074657305 |x 1535-4970 |7 nnns |
| 773 | 1 | 8 | |g volume:209 |g year:2024 |g number:7 |g day:01 |g month:04 |g pages:798-804 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1164/rccm.202309-1644CP |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 209 |j 2024 |e 7 |b 01 |c 04 |h 798-804 | ||